ClinicalTrials.gg
CompletedNCT02998528CheckMate 816Updated Jan 6, 2026Results posted

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Nivolumab and Cisplatin in Non Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 138 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
13th of 120
505 · median 66
Started
2017
with 23 others
Phase 3
24 of 120
3 open now
Registered
32nd of 120
by date
Lead sponsor
28 of 120
Bristol-Myers Squibb

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 24 that started in 2017, is one of 24 in phase 3, and was the 32nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC.

This study has multiple primary endpoints.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue
  • Lung function capacity capable of tolerating the proposed lung surgery
  • (ECOG) Performance Status of 0-1
  • Available tissue of primary lung tumor

Exclusion criteria

Exclusion Criteria:

  • Presence of locally advanced, inoperable or disease
  • Participants with active, known or suspected disease
  • Prior treatment with any drug that targets T cell co-stimulations pathways (such as )

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
505 participants (actual)

Study arms

  • Active comparator
    Platinum doublet chemotherapy

    Specified dose on specified days

    Drug: Cisplatin · Drug: Vinorelbine · Drug: Gemcitabine · Drug: Docetaxel · Drug: Pemetrexed · Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Nivolumab plus platinum doublet chemotherapy

    Specified dose on specified days

    Biological: Nivolumab · Drug: Cisplatin · Drug: Gemcitabine · Drug: Pemetrexed · Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    Nivolumab plus Ipilimumab

    Specified dose on specified days

    Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558, Opdivo

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • BiologicalIpilimumab

    This arm is closed and no longer enrolling patients.

    Also known as: BMS-734016, Yervoy

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS)

    Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)

  2. Pathologic Complete Response (pCR) Rate

    Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR).

    Time frame: From randomization up to a median of 30 months after randomization.

Secondary outcomes

  1. Major Pathologic Response (MPR) Rate

    Major pathologic response (MPR) rate is defined as number of randomized participants with \</= 10% residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR). Viable tumors in situ carcinoma should not be included in MPR calculation.

    Time frame: From randomization up to a median of 30 months after randomization.

  2. Overall Survival (OS)

    Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive.

    Time frame: From randomization to the date of death (Up to approximately 93 months)

  3. Time to Death or Distant Metastases (TTDM)

    TTDM is defined as the time between the date of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using blinded independent central review (BICR) according to response evaluation criteria in solid tumors (RECIST) 1.1. Patients who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable tumor assessment.

    Time frame: From randomization to the first date of distant metastasis or the date of death in the absence of distant metastasis (Up to approximately 84 months)

07

Results

Posted Sep 28, 2022

Participant flow

Randomization Period
Participant flow — Randomization Period
MilestoneArm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Started113213179
All concurrently randomized participants in arms b and c0179179
Completed112207176
Not completed163
Withdrew: Adverse event unrelated to study drug001
Withdrew: Participant withdrew consent030
Withdrew: Participant no longer meets study criteria132
Neoadjuvant Treatment Period
Participant flow — Neoadjuvant Treatment Period
MilestoneArm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Started111208176
All treated participants from concurrently randomized arms b and c0176176
Completed101177165
Not completed103111
Withdrew: Participant request to discontinue study treatment070
Withdrew: Participant withdrew consent040
Withdrew: Participant no longer meets study criteria010
Withdrew: Disease progression321
Withdrew: Study drug toxicity61410
Withdrew: Death100
Withdrew: Adverse event unrelated to study treatment030
Systemic Adjuvant Treatment Period
Participant flow — Systemic Adjuvant Treatment Period
MilestoneArm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Started374726
Completed284122
Not completed964
Withdrew: Disease progression100
Withdrew: Study drug toxicity451
Withdrew: Adverse event unrelated to study drug101
Withdrew: Participant request to discontinue treatment311
Withdrew: Other reasons001

Outcome measures

PrimaryEvent-Free Survival (EFS)

Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)
Reported as:
Median · Months
Event-Free Survival (EFS)
MonthsArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Event-Free Survival (EFS)20.80 (14.03 to 26.71)31.57 (30.16 to NA)
Statistical analysis
  • Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo · Log Rank · p = 0.0052 · Cox proportional hazard: 0.63 · 97.38% CI 0.43 to 0.91Stratified by PD-L1 (≥ 1% vs \<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)
PrimaryPathologic Complete Response (pCR) Rate

Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR).

Time frame:
From randomization up to a median of 30 months after randomization.
Reported as:
Count of participants · Participants
Pathologic Complete Response (pCR) Rate
ParticipantsArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Pathologic Complete Response (pCR) Rate443
Statistical analysis
  • Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo · % difference: 21.6 · 99% CI 13.0 to 30.3Strata adjusted difference (Arm C - Concurrent Arm B) based on the CMH method of weighting. Stratified by PD-L1 (≥ 1% vs \<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)
  • Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 13.94 · 99% CI 3.49 to 55.75Strata adjusted odds ratio (Arm C over Concurrent Arm B) the Mantel-Haenszel method. Stratified by PD-L1 (≥ 1% vs \<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)
Post-hocEvent-Free Survival (EFS)

Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 69 months)
Reported as:
Median · Months
Event-Free Survival (EFS)
MonthsArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Event-Free Survival (EFS)21.06 (16.53 to 36.76)59.60 (31.57 to NA)
Statistical analysis
  • Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo · Cox proportional hazard: 0.68 · 95% CI 0.51 to 0.91Stratified by PD-L1 (≥ 1% vs \<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)
SecondaryMajor Pathologic Response (MPR) Rate

Major pathologic response (MPR) rate is defined as number of randomized participants with \</= 10% residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR). Viable tumors in situ carcinoma should not be included in MPR calculation.

Time frame:
From randomization up to a median of 30 months after randomization.
Reported as:
Count of participants · Participants
Major Pathologic Response (MPR) Rate
ParticipantsArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Major Pathologic Response (MPR) Rate1666
Statistical analysis
  • Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo · % difference: 27.9 · 95% CI 19.6 to 36.1Strata adjusted difference (Arm C - Concurrent Arm B) based on the CMH method of weighting. Stratified by PD-L1 (≥ 1% vs \<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)
  • Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo · Odds ratio (or): 5.70 · 95% CI 3.16 to 10.26Stratified by PD-L1 (≥ 1% vs \<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive.

Time frame:
From randomization to the date of death (Up to approximately 93 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Overall Survival (OS)73.72 (47.34 to NA)NA (NA to NA)
SecondaryTime to Death or Distant Metastases (TTDM)

TTDM is defined as the time between the date of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using blinded independent central review (BICR) according to response evaluation criteria in solid tumors (RECIST) 1.1. Patients who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable tumor assessment.

Time frame:
From randomization to the first date of distant metastasis or the date of death in the absence of distant metastasis (Up to approximately 84 months)
Reported as:
Median · Months
Time to Death or Distant Metastases (TTDM)
MonthsArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
Time to Death or Distant Metastases (TTDM)36.76 (24.74 to 56.80)64.66 (49.02 to NA)
Statistical analysis
  • Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo · Hazard ratio (hr): 0.66 · 95% CI 0.49 to 0.90Stratified by: PD-L1 status (≥ 1% vs \<1%/not evaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)

Adverse events

Collected over All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg46/112 (41.1%)30/111 (27%)102/111 (91.9%)
Arm B: Platinum Doublet Chemo105/214 (49.1%)58/208 (27.9%)202/208 (97.1%)
Arm C: Nivo 360 mg + Platinum Doublet Chemo66/179 (36.9%)53/176 (30.1%)160/176 (90.9%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventArm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
PneumoniaInfections and infestations5/1118/2086/176
PneumonitisRespiratory, thoracic and mediastinal disorders4/1111/2081/176
Febrile neutropeniaBlood and lymphatic system disorders0/1116/2083/176
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1115/2082/176
VomitingGastrointestinal disorders0/1111/2084/176
DiarrhoeaGastrointestinal disorders2/1112/2080/176
Postoperative respiratory failureInjury, poisoning and procedural complications2/1110/2080/176
Acute kidney injuryRenal and urinary disorders0/1112/2083/176
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1111/2083/176
Post procedural complicationInjury, poisoning and procedural complications1/1111/2082/176
Most frequent other events
Showing 10 of 52
Most frequent other events
EventArm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet Chemo
NauseaGastrointestinal disorders24/111105/20873/176
AnaemiaBlood and lymphatic system disorders9/11178/20862/176
ConstipationGastrointestinal disorders24/11173/20863/176
Decreased appetiteMetabolism and nutrition disorders18/11153/20847/176
Neutrophil count decreasedInvestigations7/11146/20828/176
FatigueGeneral disorders24/11139/20830/176
NeutropeniaBlood and lymphatic system disorders1/11139/20832/176
DiarrhoeaGastrointestinal disorders18/11134/20821/176
PyrexiaGeneral disorders18/11123/20820/176
MalaiseGeneral disorders3/11126/20827/176

Baseline characteristics

All randomized participants

Age, Customized
Age, Customized(Participants)Arm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet ChemoTotal
< 65629993254
>= 65 AND < 75409675211
>= 75 AND < 8511171139
>= 850101
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet ChemoTotal
Female406551156
Male73148128349
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet ChemoTotal
Hispanic or Latino2507
Not Hispanic or Latino53105100258
Unknown or Not Reported5810379240
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Nivo 3 mg/kg + Ipi 1 mg/kgArm B: Platinum Doublet ChemoArm C: Nivo 360 mg + Platinum Doublet ChemoTotal
American Indian or Alaska Native0000
Asian419686223
Native Hawaiian or Other Pacific Islander0000
Black or African American45413
White6410889261
More than one race0000
Unknown or Not Reported4408
08

Study locations

138 sites
  • Local Institution - 0121
    Glendale, Arizona 85308, United States
  • Local Institution - 0081
    Los Angeles, California 90017, United States
  • Local Institution - 0025
    Denver, Colorado 80218, United States
  • Local Institution - 0007
    Plainville, Connecticut 06062, United States
  • Local Institution - 0173
    Hollywood, Florida 33021, United States
  • Local Institution - 0136
    Miami, Florida 33136, United States
  • Local Institution - 0054
    Orlando, Florida 32804, United States
  • Orlando Health, Inc.
    Orlando, Florida 32806, United States
  • Indian River Medical Center
    Vero Beach, Florida 32960, United States
  • Northwest Georgia Oncology Center, P.C.
    Marietta, Georgia 30060, United States
  • Local Institution - 0015
    Chicago, Illinois 60611, United States
  • Local Institution - 0002
    Chicago, Illinois 60637, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • Local Institution - 0171
    Fort Wayne, Indiana 46804, United States
  • Local Institution - 0170
    Lexington, Kentucky 40536, United States
  • Local Institution - 0186
    Louisville, Kentucky 40202, United States
  • University Medical Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Local Institution - 0151
    Baltimore, Maryland 21237, United States
  • Local Institution - 0001
    Baltimore, Maryland 21287, United States
  • Local Institution - 0008
    Boston, Massachusetts 02215, United States
  • Southcoast Center For Cancer
    Fairhaven, Massachusetts 02719, United States
  • Local Institution - 0006
    Newton, Massachusetts 02459, United States
  • Local Institution - 0012
    Detroit, Michigan 48202-2608, United States
  • Local Institution - 0090
    Hattiesburg, Mississippi 39401, United States
  • St Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • Local Institution - 0032
    Las Vegas, Nevada 89128, United States
  • Local Institution - 0009
    Hackensack, New Jersey 07601, United States
  • Valley Hospital Luckow Pavili
    Westwood, New Jersey 07675, United States
  • Local Institution - 0027
    Albany, New York 12208, United States
  • Local Institution - 0011
    New York, New York 10016, United States
  • Local Institution - 0140
    High Point, North Carolina 27262, United States
  • Christ Hospital
    Cincinnati, Ohio 45219, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Local Institution - 0149
    Zanesville, Ohio 43701, United States
  • Kaiser Permanente
    Portland, Oregon 97227, United States
  • Local Institution - 0139
    Portland, Oregon 97239, United States
  • Local Institution - 0010
    Philadelphia, Pennsylvania 19111, United States
  • Local Institution - 0018
    Pittsburgh, Pennsylvania 15212, United States
  • Local Institution - 0013
    Charleston, South Carolina 29414, United States
  • Local Institution - 0021
    Charleston, South Carolina 29425, United States
  • Local Institution - 0146
    Greenville, South Carolina 29607, United States
  • Local Institution - 0092
    Nashville, Tennessee 37203, United States
  • Local Institution - 0005
    Nashville, Tennessee 37232, United States
  • Local Institution - 0035
    Austin, Texas 78745, United States
  • Texas Oncology
    Bedford, Texas 76022, United States
  • Local Institution - 0153
    Fort Bliss, Texas 79918, United States
  • Local Institution - 0106
    Houston, Texas 77090, United States
  • Southwest Cancer Center
    Lubbock, Texas 79415, United States
  • Texas Cancer Center - Sherman
    Sherman, Texas 75090-0504, United States
  • Local Institution - 0143
    Tyler, Texas 75701, United States
  • Local Institution - 0026
    Waco, Texas 76712, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • Local Institution - 0003
    Salt Lake City, Utah 84112, United States
  • Southwest Regional Cancer Clinic
    St. George, Utah 84770, United States
  • Local Institution - 0135
    Burlington, Vermont 05405, United States
  • Local Institution - 0125
    Fairfax, Virginia 22031, United States
  • Local Institution - 0198
    Fredericksburg, Virginia 22408, United States
  • Local Institution - 0022
    Capital Federal, Buenos Aires 1426, Argentina
  • Local Institution - 0023
    Ciudad Autonoma de Buenos Aire, Buenos Aires 1181, Argentina
  • Local Institution - 0079
    Brasília, Federal District 70200-730, Brazil
  • Local Institution - 0077
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0076
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0073
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Fundacao Pio Xii Hosp Cancer De Barretos
    Barretos, São Paulo 14784-400, Brazil
  • Local Institution - 0075
    Rio de Janeiro, 22793-080, Brazil
  • Local Institution - 0095
    Gatineau, Quebec J8P 7H2, Canada
  • Local Institution - 0138
    Montreal, Quebec H2X 0A9, Canada
  • Local Institution - 0017
    Montreal, Quebec H4A 3J1, Canada
  • Local Institution - 0052
    Trois-Rivières, Quebec G8Z 3R9, Canada
  • Local Institution - 0016
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Local Institution - 0161
    Beijing, Beijing Municipality 100142, China
  • Local Institution
    Beijing, Beijing Municipality 100730, China
  • Local Institution - 0156
    Beijing, Beijing Municipality 100853, China
  • Local Institution - 0190
    Guangzhou, Guangdong 510095, China
  • Local Institution - 0192
    Changsha, Hunan 410008, China
  • Local Institution - 0175
    Changsha, Hunan 410013, China
  • Local Institution - 0193
    Changsha, Hunan 410013, China
  • Local Institution - 0179
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0166
    Nanchang, Jiangxi 330200, China
  • Local Institution
    Changchun, Jilin 130012, China
  • Local Institution - 0159
    Xi'an, Shan1xi 710061, China
  • Local Institution - 0180
    Xi'an, Shan3xi 710038, China
  • Local Institution - 0160
    Shanghai, Shanghai Municipality 200032, China
  • Local Institution - 0178
    Chengdu, Sichuan 610041, China
  • Local Institution - 0163
    Tianjin, Tianjin Municipality 300060, China
  • Local Institution - 0189
    Hangzhou, Zhejiang 310003, China
  • Local Institution - 0183
    Hangzhou, Zhejiang 310016, China
  • Local Institution - 0182
    Hangzhou, Zhejiang 310022, China
  • Local Institution - 0165
    Shanghai, 200030, China
  • Local Institution - 0059
    Marseille, 13915, France
  • Local Institution - 0060
    Paris, 75018, France
  • Local Institution - 0112
    Paris, 75248, France
  • Local Institution - 0064
    Pierre Benite Cedax, 69495, France
  • Local Institution - 0061
    Rennes, 35033, France
  • Local Institution - 0113
    Strasbourg, 67100, France
  • Local Institution - 0058
    Toulouse, 31059, France
  • Local Institution - 0062
    Tours, 37044, France
  • Local Institution - 0019
    Athens, 11527, Greece
  • Local Institution - 0122
    Thessaloniki, 57001, Greece
  • Local Institution
    Budapest, 1125, Hungary

Showing the first 100 of 138 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N; CheckMate 816 Investigators. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2025 Aug 21;393(8):741-752. doi: 10.1056/NEJMoa2502931. Epub 2025 Jun 2. PubMed 40454642 ↗
  • Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N, Provencio Pulla M. Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer. J Clin Oncol. 2025 Apr 20;43(12):1453-1462. doi: 10.1200/JCO-24-02239. Epub 2025 Jan 8. PubMed 39778121 ↗
  • Deutsch JS, Cimino-Mathews A, Thompson E, Provencio M, Forde PM, Spicer J, Girard N, Wang D, Anders RA, Gabrielson E, Illei P, Jedrych J, Danilova L, Sunshine J, Kerr KM, Tran M, Bushong J, Cai J, Devas V, Neely J, Balli D, Cottrell TR, Baras AS, Taube JM. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024 Jan;30(1):218-228. doi: 10.1038/s41591-023-02660-6. Epub 2023 Oct 30. PubMed 37903504 ↗
  • Akinboro O, Drezner N, Amatya A, Runyan J, Fourie-Zirkelbach J, Zhao M, Bi Y, Korsah K, Mixter B, Tang S, Larkins E, Pazdur R, Beaver JA, Singh H. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Jun 10;41(17):3249-3259. doi: 10.1200/JCO.22.02509. Epub 2023 May 4. PubMed 37141544 ↗
  • Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. Future Oncol. 2023 Mar;19(8):549-557. doi: 10.2217/fon-2023-0007. Epub 2023 Feb 23. PubMed 36815433 ↗
  • Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. PubMed 35403841 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Sep 2021, 54 months.

Results were first posted in Sep 2022, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 54 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2016
First posted
Dec 20, 2016
StartActual
Mar 4, 2017
Primary completionActual
Sep 8, 2021
CompletionActual
Dec 6, 2024
Results first posted
Sep 28, 2022
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02998528
Responsible party
Sponsor
First posted
Dec 20, 2016
Start date
Mar 4, 2017
Primary completion
Sep 8, 2021
Completion
Dec 6, 2024
Results posted
Sep 28, 2022
Last update
Jan 6, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cisplatin · Gemcitabine · Pemetrexed · Carboplatin · Paclitaxel · Ipilimumab

Start the discussion